UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
December 12, 2014
Date of Report (Date of earliest event reported)
 
 
GALILEO LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
333-168983
27-4677038
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
First Canadian Place
Suite 350
Toronto, Ontario
Canda
 
M5X 1C1
(Address of principal executive offices)
 
(Zip Code)
 
(416) 890 4820
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
__________
 
 
 
1
 
 
SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT
 
ITEM 5.03 AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGES IN FISCAL YEAR
 
Effective December 12, 2014, the Board of Directors of then Modern Mobility Aids, Inc., a Nevada corporation (the “Company”), pursuant to unanimous written consent board of director resolutions, authorized a change in the Company’s name to Galileo Life Sciences, Inc. (the “Name Change”). On December 12, 2014, the Company filed a Certificate of Amendment with the Nevada Secretary of State amending its articles of incorporation to reflect the change in corporate name to “Galileo Life Sciences Inc.” (the “Amendment). The Amendment was approved by the Board of Directors pursuant to written consent resolutions dated December 12, 2014 and further approved by the shareholders holding a majority of the total issued and outstanding shares of common stock of the Company pursuant to written consent resolutions dated December 12, 2014.
 
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
 
Item 9.01
Financial Statements and Exhibits
 
(a) Financial Statements of Business Acquired.
 
Not applicable.
 
(b) Pro forma Financial Information .
 
Not applicable.
 
(c) Shell Company Transaction.
 
Not applicable.
 
(d) Exhibits.
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
GALILEO LIFE SCIENCES INC. a/k/a/ MODERN MOBILITY AIDS, INC.
 

 
/s / Tito DiMarco
DATE: September 29, 2017
Name: Tito DiMarco
Title: President/Chief Executive Officer
__________
 
 
 
 
 
 
2
Modern Mobility Aids (PK) (USOTC:MDRM)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Modern Mobility Aids (PK) 차트를 더 보려면 여기를 클릭.
Modern Mobility Aids (PK) (USOTC:MDRM)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Modern Mobility Aids (PK) 차트를 더 보려면 여기를 클릭.